Wealthcare Advisory Partners’s Genomic Health, Inc. GHDX Stock Holding History

Wealthcare Advisory Partners’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-500	Closed	-$25K	–	1341
2018 Q2	$25K	Buy	+500	New	+$19.8K	﹤0.01%	626

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Wealthcare Advisory Partners's GHDX Position: Q3 2018 in Review

Wealthcare Advisory Partners sold out of Genomic Health, Inc. (GHDX) in Q3 2018, closing a stake of 500 shares — an estimated $25K sold.

Wealthcare Advisory Partners first reported a position in GHDX in Q2 2018 and held it in 1 quarter. The position peaked at $25K in Q2 2018. 201 funds tracked by Wall St. Rank hold GHDX as of Q3 2018.

Wealthcare Advisory Partners reported no remaining Genomic Health, Inc. position as of Q3 2018 after selling out during the quarter.
Wealthcare Advisory Partners sold 500 Genomic Health, Inc. shares in Q3 2018, an estimated $25K.
Wealthcare Advisory Partners first reported a position in Genomic Health, Inc. in Q2 2018 and held it in 1 quarter.
Wealthcare Advisory Partners's Genomic Health, Inc. position peaked at $25K in Q2 2018.
201 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q3 2018.

Based on Wealthcare Advisory Partners's 13F filing for Q3 2018, filed 14 Nov 2018.